Feasibility of the Switch From Rivastigmine Capsules to Rivastigmine Transdermal Patch: Randomized, Open Label, Controlled Multicenter Study.

Trial Profile

Feasibility of the Switch From Rivastigmine Capsules to Rivastigmine Transdermal Patch: Randomized, Open Label, Controlled Multicenter Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Rivastigmine; Rivastigmine
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms KAPA
  • Sponsors Novartis
  • Most Recent Events

    • 23 Mar 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 10 Jul 2010 Results presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
    • 05 Jun 2009 Planned number of patients changed from 144 to 142 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top